Chemistry:OPC-64005
OPC-64005 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), or "triple reuptake inhibitor" (TRI), which is under development for the treatment of major depressive disorder.[1][2][3] It was also under development for the treatment of attention deficit hyperactivity disorder (ADHD), but development for this indication was discontinued.[1][4] It is taken by mouth.[1]
As of December 2022, OPC-64005 is in phase 2 clinical trials for major depressive disorder.[1][2] It reached phase 2 clinical trials for ADHD prior to the discontinuation of its development for this use.[1] It completed a phase 2 clinical trial for ADHD comparing it with placebo and atomoxetine, but the results of this trial were not disclosed.[5] The drug is under development by Otsuka Pharmaceutical.[1][2] It is a small molecule, but its chemical structure does not appear to have been disclosed.[1][2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "OPC 64005". 7 December 2022. https://adisinsight.springer.com/drugs/800045471.
- ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on OPC-64005 with Synapse". 17 October 2024. https://synapse.patsnap.com/drug/52a1e42cb66e4c6792d8e1066b5aafdf.
- ↑ "A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands". Curr Med Chem 29 (29): 4896–4922. August 2022. doi:10.2174/0929867329666220317121551. PMID 35301942.
- ↑ "Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD". Expert Rev Neurother 19 (7): 707–717. July 2019. doi:10.1080/14737175.2019.1628640. PMID 31167583. https://eprints.soton.ac.uk/431813/1/ERN_main_text_R1_BLACK.doc.
- ↑ "Adult attention deficit hyperactivity disorder: a comprehensive review". Ann Med Surg (Lond) 85 (5): 1802–1810. May 2023. doi:10.1097/MS9.0000000000000631. PMID 37228994.
 |  |
